News Background

Oxford, UK – 11 October 2016. OGT, The Molecular Genetics Company, has today announced a significant expansion of its existing catalogue of CytoCell® Haematology probes for fluorescence in situ hybridisation (FISH) — underlining the company's position as the one-stop-shop for high-quality FISH probes. These additions have been introduced due to an ongoing commitment to use customer input as a major driver for the rapid development of the latest research-relevant probes. The 14 newly launched probes are:

  • RUNX1 Probe Green
  • NUP98 Proximal Probe Red
  • NUP98 Distal Probe Green
  • TET2 Probe Red
  • TERT (5p15.33) Probe Aqua
  • CUX1 (7q22) Probe Green
  • EZH2 (7q36) Probe Red
  • Chromosome 7 Alpha Satellite Probe Aqua

The new cost-effective and quality-assured probes are optimised for use on common sample types and are sold as pre-mixed, easy-to-use formulations to minimise experimental errors. The importance of researchers’ input in today’s announcement demonstrates the ongoing success of OGT’s myProbes® service, which enables scientists to order custom-made probes for virtually any sequence in the human genome. All probes are produced under GMP/GLP guidelines using the CytoCell BAC-2-FISH™ process, combining high-intensity signals with low levels of background fluorescence and providing maximum confidence in results.

As the longest-standing FISH probe manufacturer in the world, 2016 marks 25 years of CytoCell expertise and customer service in the development and production of FISH products. “myProbes gives us the opportunity to get continuous input from our customers,” explains Faidra Partheniou, Haematology Product Manager at OGT, “it truly helps us to respond quickly to changes in customer demand and it helps researchers by providing a first port of call for rapid development of new probes. These latest additions to our CytoCell portfolio are testament to this.”

OGT also offers the opportunity to evaluate the accurate, user-friendly FISH probes in customer’s own labs free of charge by simply requesting up to four free probes from their extensive range. 

The new additions to the CytoCell haematology probe range are currently only available within North America as analyte specific reagents (ASRs), analytical and performance characteristics are not established. CE-marked IVD versions for sale in Europe are anticipated.

About OGT

OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.

 

For more information on the Company, please visit our website at ogt.com

 

CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.

 

About Sysmex Corporation

Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.

 

For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.

Related content

  • Share

You might also be interested in

OGT's CytoCell portfolio available via Sysmex in China and Spain Listing Image

OGT's CytoCell portfolio available via Sysmex in China and Spain

06 Jul 2020

Addition of direct-sales territories follows successes across Europe and APAC and provides customers with enhanced local sales and support services.

Read
OGT celebrates opening of new Cambridge site Listing Image

OGT celebrates opening of new Cambridge site

06 Jun 2019

State-of-the-art premises increases operational footprint and will host Sysmex global R&D facility.

Read
OGT continues move into molecular diagnostics markets Listing Image

OGT continues move into molecular diagnostics markets

18 Nov 2019

MDSAP certification of new Cambridge facility smooths path to future IVD approvals.

Read
All News
CTA Icon

Stay up-to-date with the latest news from OGT, including new products, support resources, and our DNA Dispatch newsletter